Table 1: Immunoreactivity of atheroma plaques to anti-OPG, anti-RANK, anti-RANKL and anti-CD68 antibodies

|  |  |  | Immunostaining |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Patients | Gender | Bed | OPG | RANK | RANKL | CD68 |
| 1 | M | C | +, calcifications | +, LC, calcifications, MC | ++, calcifications, EC, MC | ++ |
| 2 | M | C | +, calcifications | +, LC | +, calcifications, LC | ++ |
| 3 | M | F | - | ++, LC, EC | ++, calcifications, LC | + |
| 4 | M | C | +, LC | ++, LC, EC, MC | +, LC, EC, MC | +++ |
| 5 | F | C | +, LC | ++, LC, EC, MC | ++, LC, EC, MC | +++ |
| 6 | F | C | +, LC | ++, LC, EC, MC | ++, LC, EC, MC | ++ |
| 7 | M | F | - | ++, calcifications, LC, EC, MC | +, EC | + |
| 8 | M | C | +, LC | +, LC, MC | ++, LC, EC, MC | ++ |
| 9 | M | C | - | +, LC, MC | +, calcifications, EC | ++ |
| 10 | M | F | - | +, calcifications | +, calcifications, EC | + |
| 11 | M | F | ++, calcifications and EC | +, LC, EC, MC | +, calcifications, EC | + |
| 12 | F | F | - | ++, calcifications | +, EC | + |
| 13 | M | C | +, EC and VSMC | ++, LC, EC, MC | ++, calcifications, EC, MC | $+$ |
| 14 | M | C | ++, LC, calcifications, MC | ++, LC, MC | ++, calcifications, EC, MC | ++ |
| 15 | M | C | +, calcifications | ++, LC, MC | $\begin{aligned} & \hline++, \text { calcifications, LC, EC, } \\ & \text { VSMC } \end{aligned}$ | ++ |
| 16 | M | C | +, VSMC | +, LC, MC | ++, LC, EC, MC | ++ |
| 17 | M | C | ++, LC, VSMC | ++, LC, EC, MC, VSMC | ++, calcifications, LC, EC, MC | ++ |
| 18 | M | C | ++, LC, EC, MC | ++, LC, EC, MC, VSMC | ++, LC, EC, MC | ++ |
| 19 | M | F | ++, calcifications and EC | +, calcifications | ++, calcifications, EC, MC | + |
| 20 | M | C | - | ++, LC, EC, MC | +, calcifications, EC, VSMC | + |
| 21 | F | F | ++, calcifications, EC | +++, calcifications, MC, OC | ++, calcifications, EC, MC | + |
| 22 | M | C | +, LC | ++, LC, EC, MC | $\begin{aligned} & \text { ++, calcifications, EC, MC, } \\ & \text { VSMC } \end{aligned}$ | ++ |
| 23 | M | F | ++, calcifications, EC, MC | +, EC | ++, calcifications, EC, MC | + |
| 24 | F | C | +, calcifications, LC | ++, calcifications, EC, MC | +, calcifications, EC, VSMC | ++ |
| 25 | M | F | ++, calcifications, EC, MC | +, LC, MC, OC | ++, calcifications, EC, MC | + |
| 26 | M | C | - | ++, calcifications, LC, MC | ++, calcifications, EC, MC | + |
| 27 | M | C | - | +, LC, MC | ++, LC, EC, MC | +++ |
| 28 | M | C | - | +, MC | +, MC | ++ |
| 29 | F | F | ++, calcifications, EC, MC | +, calcifications | - | + |
| 30 | M | F | +, calcifications, EC, MC | ++, calcifications, EC | ++, Calcifications, EC, MC | + |


| 31 | M | C | - | +, calcifications | +, calcifications, EC | + |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 32 | M | F | +, EC, MC | +, EC, VSMC | +, calcifications, EC, MC | + |
| 33 | M | F | +, calcifications, EC | +++, calcifications,EC, MC, VSMC | ++calcifications, EC, VSMC | + |
| 34 | M | F | - | +, EC, VSMC | +, VSMC | - |
| 35 | M | F | - | ++, calcifications, LC, EC, MC, VSMC | ++, calcifications, EC, VSMC | + |
| 36 | M | F | - | +, calcifications | ++, calcifications, EC, VSMC | + |
| 37 | M | F | - | ++, calcifications, MC | ++, calcifications, EC, VSMC | + |
| 38 | M | F | - | +, calcifications | +, VSMC | + |
| 39 | F | F | - | - | ++, calcifications, EC, VSMC | + |
| 40 | F | F | +, calcifications | +++, EC, MC, VSMC | ++, calcifications, EC, VSMC | + |

LC : lipid core ; EC : endothelial cell ; VSMC : vascular smooth muscle cell ; MC : macrophage ; OC : osteoclast $(-)$ absence or negligible signal ; (+) weak signal ; $(++)$ moderate signal ; $(+++)$ strong signal

